| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004178 | American Journal of Ophthalmology | 2009 | 12 Pages |
Abstract
Azathioprine was moderately effective as a single corticosteroid-sparing immunosuppressive agent in terms of control of inflammation and corticosteroid-sparing benefits, but required several months to achieve treatment goals; it seems especially useful for patients with intermediate uveitis. Treatment-limiting side effects occurred in approximately one-fourth of patients within 1 year, but typically were reversible.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Sirichai Pasadhika, John H. Kempen, Craig W. Newcomb, Teresa L. Liesegang, Siddharth S. Pujari, James T. Rosenbaum, Jennifer E. Thorne, C. Stephen Foster, Douglas A. Jabs, Grace A. Levy-Clarke, Robert B. Nussenblatt, Eric B. Suhler,